KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $13,016.78. Following the completion of the sale, the chief financial officer now owns 68,581 shares of the company’s stock, valued at approximately $523,273.03. The trade was a 2.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KALA BIO Price Performance

Shares of NASDAQ:KALA traded up $0.16 during midday trading on Tuesday, hitting $7.69. 45,377 shares of the stock were exchanged, compared to its average volume of 105,019. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. The stock has a market cap of $35.45 million, a P/E ratio of -0.62 and a beta of -2.11. The company has a 50 day moving average price of $6.71 and a 200-day moving average price of $6.32. KALA BIO, Inc. has a twelve month low of $4.21 and a twelve month high of $9.25.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. On average, research analysts forecast that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a report on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.